| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | 痰湿体质医学配方食品 | CN201510171572.0 | 2015-04-13 | CN105029403A | 2015-11-11 | 陈昕; 秦孝发; 吴灿; 胡安然; 蔡缨 |
| 本发明属于药食同源类配方与新资源食品技术领域，具体是提供了供痰湿体质患者食用的医学配方食品、特定医学配方食品或非特定医学方食品；该配方根据《特殊医学用途配方食品通则》的要求，结合痰湿体质患者的体质特征，根据传统中医精髓理论合理配伍多种“药食同源”之中药,采用多种经预水解SBE技术提取药食两用的中药提取物精华、多种微胶囊化的益生菌以及生物酶解提取的短肽、益生元、氨基酸、碳水化合物、有保健功能的油脂、多种维生素及矿物质一起混合等工艺加工制成，不仅可作为单一营养来源满足痰湿体质患者的营养需求，还起到了健脾益气、燥湿利水、清热排脓、生津益肺，补肾涩精、补脾养胃及增强免疫力功效。 | ||||||
| 42 | 脾胃虚寒医学配方食品 | CN201510168079.3 | 2015-04-10 | CN105029399A | 2015-11-11 | 陈昕; 秦孝发; 吴灿; 胡安然; 蔡缨 |
| 本发明属于药食同源类配方与新资源食品技术领域，具体是提供了供脾胃虚寒患者食用的医学配方食品、特定医学配方食品或非特定医学方食品；该配方根据《特殊医学用途配方食品通则》的要求，结合脾胃虚寒患者的体质特征，根据传统中医精髓理论合理配伍多种“药食同源”之中药,采用多种经预水解SBE技术提取药食两用的中药提取物精华、多种微胶囊化的益生菌以及生物酶解提取的短肽、益生元、氨基酸、碳水化合物、有保健功能的油脂、多种维生素及矿物质一起混合等工艺加工制成，不仅可作为单一营养来源满足脾胃虚寒患者的营养需求，还起到了理气温里、行气止痛、暖脾止泻、消积化滞、温脾止泻、渗湿利水及增强免疫力功效。 | ||||||
| 43 | 慢性阻塞性肺疾病特定全营养配方食品 | CN201510198872.8 | 2015-04-24 | CN104996994A | 2015-10-28 | 胡安然; 陈昕; 吴灿; 王慧 |
| 本发明属于药食同源类配方与新资源食品技术领域，具体是提供了慢性阻塞性肺疾病特定全营养配方食品；该配方根据《特殊医学用途配方食品通则》的要求，结合慢性阻塞性肺疾病患者的体质特征，根据传统中医精髓理论合理配伍多种“药食同源”之中药,采用多种经预水解SBE技术提取药食两用的中药提取物精华、多种微胶囊化的益生菌以及生物酶解提取的短肽、益生元、氨基酸、碳水化合物、有保健功能的油脂、多种维生素及矿物质一起混合等工艺加工制成，不仅可作为单一营养来源满足慢性阻塞性肺疾病患者的营养需求，还起到了健脾益肺、清热解毒、补中益气、化痰止咳、补肺清热及防治慢性阻塞性肺疾病的功效。 | ||||||
| 44 | 阴虚体质医学配方食品 | CN201510171586.2 | 2015-04-13 | CN104996993A | 2015-10-28 | 陈昕; 秦孝发; 吴灿; 胡安然; 蔡缨 |
| 本发明属于药食同源类配方与新资源食品技术领域，具体是提供了供阴虚体质患者食用的医学配方食品、特定医学配方食品或非特定医学方食品；该配方根据《特殊医学用途配方食品通则》的要求，结合阴虚体质患者的体质特征，根据传统中医精髓理论合理配伍多种“药食同源”之中药,采用多种经预水解SBE技术提取药食两用的中药提取物精华、多种微胶囊化的益生菌以及生物酶解提取的短肽、益生元、氨基酸、碳水化合物、有保健功能的油脂、多种维生素及矿物质一起混合等工艺加工制成，不仅可作为单一营养来源满足阴虚体质患者的营养需求，还起到了补血滋阴、养阴润燥、润肺生津、清心安神、清热解表、健脾养胃及增强免疫力功效。 | ||||||
| 45 | 乳酸菌培养物以及其制造方法 | CN201380017224.7 | 2013-03-27 | CN104379728A | 2015-02-25 | 星亮太郎; 松井彰久; 铃木贵雄 |
| 本发明的目的在于，提供维持甜茶提取物在乳酸菌的培养中的提高增殖性、存活性的效果并改善风味的技术，提供一种乳酸菌培养物，其特征在于，其是在含有甜茶精的培养基中培养乳酸菌而得到的，所述甜茶精是对在甜茶提取物中添加了无机盐的物质进行电渗析从而以浓缩液的形式得到的。 | ||||||
| 46 | 妇女延更调理全营养配方食品 | CN201410402562.9 | 2014-08-16 | CN104256633A | 2015-01-07 | 胡安然 |
| 本发明提供了供更年期妇女食用的全营养配方食品、特定全营养配方食品或非全营养配方食品。该配方根据《特殊医学用途配方食品通则》的要求，结合更年期妇女的体质特征，综合当今美国哈佛大学的先进生理学、医药、营养学及临床应用等研究成果，依据“消中寓补”、“均衡调养”的传统中医的精髓理论(肝、脾、肾三脏同调为主原则)研制而成。该产品采用多种药食两用的中药提取物精华、多种益生菌、短肽为主要原料，以益生元、碳水化合物、氨基酸、多种维生素及矿物质为辅料混合而成，不仅可作为单一营养来源满足更年期妇女的营养需求，还有起到活血祛瘀、调经止痛、开淤散结、养心、益阴、安神、镇潜及增强免疫力的功效。 | ||||||
| 47 | 子宫癌全营养配方食品 | CN201410575369.5 | 2014-10-25 | CN104256629A | 2015-01-07 | 胡安然 |
| 本发明提供了供子宫癌患者食用的全营养配方食品、特定全营养配方食品或非全营养配方食品。该配方根据《特殊医学用途配方食品通则》的要求，结合子宫癌患者的体质特征，采用多种经预水解SBE技术提取药食两用的中药提取物精华、多种微胶囊化的益生菌以及生物酶解提取的短肽、益生元、氨基酸、碳水化合物、多种维生素及矿物质一起粉碎混合而成，不仅可作为单一营养来源满足子宫癌患者的营养需求，还有起到平肝清热，益气健脾，固摄止血。活血行瘀，理气止痛、育阴滋肾及增强免疫力的功效。 | ||||||
| 48 | 一种肠道炎症性疾病防治的肠道微生态制剂 | CN201410134266.5 | 2014-04-04 | CN104222732A | 2014-12-24 | 胡安然 |
| 本发明属于药食同源类配方食品技术领域，具体是一种肠道炎症性疾病防治的微生态制剂。根据肠道炎的体质特征，利用中医体质平衡原理，合理配伍山药、芡实、米仁、鸡内金、石斛、白术、木香、白豆蔻、厚朴花等，将其浸泡后加入β-环状糊精，用预水解SBE技术提取并浓缩后，配以水苏糖、芡实、糊精100℃干燥并灭菌6小时，配以L-谷氨酰胺粉碎并混合后进行巴氏灭菌1小时，然后添加微胶囊化后益生菌、酵母混合的工艺制成固体饮料，也可制成胶囊、方便食品。本发明的优势在于能通过饮食调节恢复人体平衡，达到稳定健康状态，减小致肠道炎相关病症发展的效果。 | ||||||
| 49 | 促进血中脂连蛋白浓度增加及/或抑制其减少的制剂及内脏脂肪蓄积抑制剂 | CN200780032782.5 | 2007-08-30 | CN101678051B | 2012-12-12 | 川上浩; 日暮聪志; 松山博昭 |
| 本发明涉及一种促进血中脂连蛋白浓度增加及/或抑制其减少的制剂，以及一种促进血中脂连蛋白浓度增加及/或抑制其减少用饮食品、饲料，其以乳杆菌属乳酸菌特别是以其中的加氏乳杆菌与瑞士乳杆菌的培养物或其菌体自身作为有效成分。另外本发明涉及一种内脏脂肪蓄积抑制剂及抑制内脏脂肪蓄积用饮食品，其以瑞士乳杆菌的培养物或其菌体自身作为有效成分。 | ||||||
| 50 | 具有高的草酸分解能力的乳酸菌 | CN200980138609.2 | 2009-09-29 | CN102171329A | 2011-08-31 | 越智大辅; 坪井洋 |
| 本发明提供具有比以往已知的具有草酸分解活性的乳酸菌高数倍的草酸分解活性的乳酸菌及其用途。由从成人的粪便和胃液单独分离的乳杆菌属乳酸菌132菌株中筛选出可大量分解草酸的乳酸菌。其结果，发现了具有下述特征的乳酸菌：在含有10mM草酸的培养液中、37℃、培养开始时的pH为6.5的条件下培养72小时时的草酸分解率为50％以上。 | ||||||
| 51 | FORMULATIONS FOR BENEFICIALLY ALTERING THE MICROBIOME | US15087426 | 2016-03-31 | US20160287644A1 | 2016-10-06 | David H. Rahm |
| Several embodiments of the invention provide a unique system of formulations adapted to beneficially alter the microbiome. In one embodiment, the invention comprises four oral formulations designed to work synergistically to assist in weight management. The formulations include three or four of the following: a cleansing formulation, a prebiotic formulation a probiotic formulation and a nutritional formulation. The formulations can be designed to work together to fundamentally change the flora of the gastrointestinal tract to achieve significant benefits. | ||||||
| 52 | Lactic acid bacterium having high oxalic acid decomposition ability | US13119382 | 2009-09-29 | US09283252B2 | 2016-03-15 | Daisuke Ochi; Hiroshi Tsuboi |
| The present invention provides lactic acid bacteria having oxalic acid-degrading activity several times higher than those of conventionally known lactic acid bacteria having an oxalic acid-degrading activity, and uses thereof. Lactic acid bacteria capable of degrading a large amount of oxalic acid were screened from 132 strains of Lactobacillus lactic acid bacteria that have been independently isolated from feces and gastric juices of human adults. As a result, lactic acid bacteria having an oxalic acid degradation rate of 50% or more when cultured at 37° C. for 72 hours in a culture medium containing 10 mM oxalic acid at pH 6.5 at the start of culture were discovered. | ||||||
| 53 | Feed composition | US10552542 | 2004-04-08 | US09113642B2 | 2015-08-25 | Yoshihito Hagawa; Yasunori Kagawa; Kiyotaka Sakai; Takenori Orihashi; Yukimasa Kishimura; Michio Kanbe |
| A feed supplement comprising at least one selected from lactic acid bacterium belonging to Lactobacillus gasseri, a crushed product of the lactic acid bacterium, culture of the lactic acid bacterium, residue of the culture of the lactic acid bacterium and a treated product thereof (a concentrate, a pasted product, a dried product, a liquid product, a diluted product, a sterilized product, etc.) and a feed composition comprising the feed supplement. | ||||||
| 54 | Method for culturing lactic acid bacterium and method for producing fermented milk | US13260254 | 2010-03-26 | US08709516B2 | 2014-04-29 | Kakuhei Isawa; Masayuki Kamijo |
| A method for culturing lactic acid bacteria includes (a) adding a proteolytic enzyme to an aqueous whey solution containing whey and water to thereby prepare a culture solution containing whey degraded by the proteolytic enzyme; (b) inoculating the culture solution with Lactobacillus gasseri which is a bacteriocin-producing lactic acid bacteria; and (c) maintaining the culture solution inoculated with the bacteriocin-producing lactic acid bacteria at a pH of not lower than 5.2 and not higher than 5.8 to provide cultured lactic acid bacteria. After the completion of culturing, the culture solution is centrifuged to separate a concentrated cell suspension containing the lactic acid bacterium in a concentrated form. The concentrated cell suspension has extremely high antibacterial activity, several tens of thousands AU, and is usable as a food preservative. Yogurt is produced by fermenting a yogurt mix to which 0.01% to 0.1% by weight of the concentrated cell suspension is added. | ||||||
| 55 | Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation | US12376368 | 2007-05-14 | US08309076B2 | 2012-11-13 | Ji Hee Kang; Byeung Il You; Sung Il Yun; Han Oh Park |
| The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining. | ||||||
| 56 | BLOOD-ADIPONECTIN-CONCENTRATION INCREASE-ACCELERATOR AND/OR DECREASE-INHIBITOR THEREOF AND VISCERAL FAT ACCUMULATION INHIBITOR | US13236034 | 2011-09-19 | US20120009165A1 | 2012-01-12 | Hiroshi KAWAKAMI; Satoshi HIGURASHI; Hiroaki MATSUYAMA |
| Disclosed is an agent for accelerating the increase in and/or preventing the decrease in the blood adiponectin level, or a food, beverage or animal feed for accelerating the increase in and/or preventing the decrease in the blood adiponectin level, which comprises a culture or cell of a lactic acid bacterium belonging to the genus Lactobacillus, particularly Lactobacillus gasseri or Lactobacillus helveticus as an active ingredient. Also disclosed is a visceral fat accumulation inhibitor or a food or beverage for inhibiting the accumulation of a visceral fat, which comprises a culture or cell of Lactobacillus helveticus as an active ingredient. | ||||||
| 57 | LACTIC ACID BACTERIUM HAVING HIGH OXALIC ACID DECOMPOSITION ABILITY | US13119382 | 2009-09-29 | US20110236360A1 | 2011-09-29 | Daisuke Ochi; Hiroshi Tsuboi |
| The present invention provides lactic acid bacteria having oxalic acid-degrading activity several times higher than those of conventionally known lactic acid bacteria having an oxalic acid-degrading activity, and uses thereof. Lactic acid bacteria capable of degrading a large amount of oxalic acid were screened from 132 strains of Lactobacillus lactic acid bacteria that have been independently isolated from feces and gastric juices of human adults. As a result, lactic acid bacteria having an oxalic acid degradation rate of 50% or more when cultured at 37° C. for 72 hours in a culture medium containing 10 mM oxalic acid at pH 6.5 at the start of culture were discovered. | ||||||
| 58 | Human ABO Blood Group-Binding Lactobacilli | US12987518 | 2011-01-10 | US20110104721A1 | 2011-05-05 | Tadao Saito; Yasushi Kawai; Hideaki Uchida; Katsunori Kimura; Kakuhei Isawa; Keisuke Furuichi |
| Lactobacillus screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 lactobacillus strains, the above-mentioned screening methods and tests to judge their compatibility for the use of yogurt production were carried out, to at long last specifically discover bacillus strains compatible with blood groups A, B, and O. | ||||||
| 59 | Human Abo Blood Group-Binding Lactobacilli | US11720462 | 2005-12-01 | US20080160565A1 | 2008-07-03 | Tadao Saito; Yasushi Kawai; Hideaki Uchida; Katsunori Kimura; Kakuhei Isawa; Keisuke Furuichi |
| Lactobacillus screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 lactobacillus strains, the above-mentioned screening methods and tests to judge their compatibility for the use of yogurt production were carried out, to at long last specifically discover bacillus strains compatible with blood groups A, B, and O. | ||||||
| 60 | Feed composition | US10552542 | 2004-04-08 | US20060204553A1 | 2006-09-14 | Yoshihito Hagawa; Yasunori Kagawa; Kiyotaka Sakai; Takenori Orihashi; Yukimasa Kishimura; Michio Kanbe |
| A feed supplement comprising at least one selected from lactic acid bacterium belonging to Lactobacillus gasseri, a crushed product of the lactic acid bacterium, culture of the lactic acid bacterium, residue of the culture of the lactic acid bacterium and a treated product thereof (a concentrate, a pasted product, a dried product, a liquid product, a diluted product, a sterilized product, etc.) and a feed composition comprising the feed supplement. | ||||||
QQ群二维码
意见反馈
意见反馈